The Role Of Hepatic Rho-kinase In Regulating Glucose And Lipid Homeostasis | 36322
Journal of Obesity & Weight Loss Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with obesity and insulin resistance and ultimately
leads to cirrhosis and other complications. However, the pathogenesis of this disease has not yet been fully understood.
In our studies, mice with liver-specific Rho-kinase 1 (ROCK1) deletion were used to examine role of ROCK1 in regulating
hepatic glucose homeostasis and lipid metabolism. Our results show that hepatic ROCK1-deficiency leads to reduced body
weight, improved insulin sensitivity and hepatic steatosis in diet-induced obese mice. These changes are associated with a
decreased lipogenic rate in the ROCK1-deficient primary hepatocytes compared to control hepatocytes using 14C-lactate as a
lipogenic substrate. These data are further supported by the experimental evidence that ROCK1 deletion in the liver causes a
significant suppression in expression of key lipogenic enzymes, including FAS, SCD1, Elovl2 and SREBP-1c. In addition, the
up-regulation of hepatic ROCK1 expression and activity and hepatic steatosis induced by a high-fat diet are greatly reduced
after metformin treatment. Consistent with the in vivo data, treating hepatocytes with metformin markedly reduces ROCK1
expression and activity in a dose-dependent manner and decreases expression of lipogenic enzymes and the rate of de novo
lipogenesis. Collectively, these data identify hepatic ROCK1 as a key regulator of fat metabolism and further demonstrate that
inhibition of hepatic ROCK1 could be a novel therapeutic approach for the treatment of NAFLD.
Hu Huang has completed his PhD from University of Tsukuba, Japan and postdoctoral studies from Beth Israel Deaconess Medical Center and Harvard Medical School. He has published more than 15 papers in reputed journals and serving as an editorial board member of repute. He is assistant professor at East Carolina Diabetes and Obesity Institute & East Carolina University. His laboratory seeks to understand basic molecular mechanisms underlying the metabolic syndrome, including obesity, insulin resistance, impaired glucose metabolism and non-alcoholic fatty liver disease.